Fusion proteins comprising HIV-1 Tat and/or Nef proteins
AssigneeSmithKline Beecham Biologicals s.a.
InventorsClaudine Bruck, Stephane Godart, Martine Marchand
Life of this patent
Estimating the term…
Abstract
The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or derivative thereof; or (c) an HIV Nef protein or derivative thereof linked to an HIV Tat protein or derivative thereof and a fusion partner. The invention further provides for a nucleic acid encoding such a protein and a host cell, such as Pichia Pastoris, transformed with the aforementioned nucleic acid
Claims23
to 31 cancelled.
An immunogenic composition which comprises a fusion protein comprising an HIV Tat protein or a mutant thereof linked to an HIV Nef protein, wherein the HIV Tat protein or a mutant thereof and the HIV Nef protein are linked in any orientation, wherein the mutant of the HIV Tat protein is biologically inactive while maintaining its immunogenic epitopes and bears mutations in the active site and RGD motif, wherein the fusion protein is optionally linked to a fusion partner, and wherein the fusion protein is in admixture with a pharmaceutically acceptable excipient.
A protein comprising an HIV Tat protein or a mutant thereof linked to an HIV Nef protein in Nef-Tat or Tat-Nef orientation, wherein the mutant of the HIV Tat protein is biologically inactive while maintaining its immunogenic epitopes and bears mutations in the active site and RGD motif.
Dependencies are inferred from the claim text.